Press release
Rosa’s Christina Friedrich to Lead Model Qualification Workshop at ICSB 2011
The Model Qualification Method is a rigorous, systematic analysis of model relevance, uncertainty, variability, and consistency with data to ensure drug discovery/development models are “fit for purpose”Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will be leading a workshop on its Model Qualification Method (MQM) at the 12th International Conference on Systems Biology (ICSB), the major event for the world-wide systems biology community, in Heidelberg/Mannheim, Germany on August 28, 2011.
Mechanistic physiological modeling such as Rosa’s PhysioPD™-style approach is employed by pharmaceutical companies to support decisions at every step of the drug development pipeline. In order to meet future regulatory and internal scientific demands, a method is needed to qualify the models. Drawing on decades of experience, Rosa has developed the MQM to ensure that questions of model relevance and scope, uncertainty and variability, and use of and consistency with both qualitative and quantitative data are addressed in a rigorous and systematic fashion, so that model-based research can proceed with confidence.
In a well-planned and executed modeling project, model qualification cannot be left as an exercise at the end of the project; rather, the entire project should be set up with the MQM in mind. The workshop will take participants step-by-step through the process of planning, building and qualifying mechanistic physiological models for use in drug discovery and development. Participants will thus be equipped to take first steps toward building such models, and empowered to ask the right questions to ensure that any models built for drug discovery and development are “fit for purpose.”
“A quality standard such as the MQM is necessary to support the broad-scale adoption and impact of mechanistic physiological PhysioPD-style modeling. A standard for judging “fitness for purpose” is long overdue, and we are proud to build on our decades of experience in this type of modeling, and to lead the promulgation of the MQM. We look forward to sharing our ideas with the workshop participants.” said Dr. Ron Beaver, Rosa’s Founder and CEO.
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
751 Laurel St., Ste. 127,
San Carlos, CA 94070
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rosa’s Christina Friedrich to Lead Model Qualification Workshop at ICSB 2011 here
News-ID: 185293 • Views: …
More Releases for MQM
United States Target Drone Market to Reach $7.69 Billion by 2031, Driven by Adva …
The Global Target Drone Market reached US$ 4.47 billion in 2023 and is expected to reach US$ 7.69 billion by 2031, growing at a CAGR of 7.02% during the forecast period 2024-2031.
The target drone market focuses on the development and deployment of unmanned aerial vehicles used for training, surveillance, and testing military defense systems. These drones simulate real-world aerial threats for weapon system accuracy assessment. They are designed for durability,…
Alconost Redefines Localization with Cutting-Edge Solutions for Global Businesse …
Image: https://www.abnewswire.com/upload/2025/01/465330d5f8b8b0b648818f5e7cbd0bdf.jpg
For today's localization companies, there is more than just translation. Performance analytics and measurement are no longer optional to stay competitive and grow.
KPIs are easily quantified measures for agencies to track what's working and what's not, improve efficiency, and show their worth to clients. Such KPIs enable rational choices to highlight areas of improvement.
The article explains five KPIs that localization companies must track at all times. These are client…
Magnetic Jack Market Expansion at 5.53% CAGR by 2032
The Magnetic Jack market, valued at approximately USD 1.91 billion in 2023, is projected to experience substantial growth in the coming years. The industry is expected to expand from USD 2.02 billion in 2024 to reach USD 3.1 billion by 2032. This growth trajectory reflects a robust compound annual growth rate (CAGR) of around 5.53% during the forecast period from 2024 to 2032.
Key Companies in the Magnetic Jack Market Include:
Apex…
Rosa to Present Mechanistic Systems Pharmacology Workshop at 2012 ICSB Conferenc …
Workshop focused on Rosa’s Model Qualification Method to be held August 19th, Toronto, Canada.
Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present a mechanistic systems pharmacology workshop at ICSB-2012 - the 13th International Conference on Systems Biology in Toronto, Canada on August 19th, 2012. Dr. Christina Friedrich will be presenting the workshop entitled "Using Mechanistic Systems Pharmacology…
Rosa to present two lectures at The European Foundation of Medicinal Chemists Co …
Rosa to Present The MQM Standard and Lead Optimization Using Systems Pharmacology Modeling
Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present two lectures entitled "Optimizing Lead Compound Selection Using Mechanistic Physiological Modeling" and "Qualifying Mechanistic Physiological Models for Use in Pharmaceutical Discovery and Development" on April 2, 2012, as part of the European Foundation of Medicinal Chemists…
Rosa to Present Systems Pharmacology Workshop at 3rd Annual World PK/PD Summit
Rosa Workshop Presents The MQM Quality Standard For Mechanistic Modeling
Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present a pre-conference workshop entitled “Development of Mechanistic Systems Pharmacology Modeling for Insight and Decision Support” on Tuesday, 27 March 2012, as part of the 3rd Annual World PK/PD Summit, March 27 – 29, 2012 in Boston. Dr. Christina Friedrich…